

## ASIT biotech conference calendar H2 2019

**Brussels, Belgium, 10 September 2019, 07.00 am (CET) – ASIT biotech (ASIT - BE0974289218)**, a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough allergy immunotherapy products, is on track to report the results of its Phase III gp-ASIT+™ for grass pollen rhinitis in December 2019 and preparing next development steps.

To engage the national and international investor community, ASIT biotech will conduct an intensive investor outreach program, as well as participate in multiple upcoming industry conferences in the second half of 2019.

<b>Event</b>	<b>Date</b>	<b>Location</b>
MidCap Event	20-Sep	Amsterdam, NL
Non-deal investor roadshow	23-Sep	Milano, IT
Non-deal investor roadshow	25-Sep	Monaco, MC
Dag van de Tips	28-Sep	Ghent, BE
Non-deal investor roadshow	2-Oct	Paris, FR
Non-deal investor roadshow	3-Oct	Geneva, CH
Non-deal investor roadshow	4-Oct	Zurich, CH
Large & Midcap Event	15-Oct	Paris, FR
Agora Biotech Event	22-Oct	Paris, FR
Non-deal investor roadshow	5-Nov	Brussels, BE
Non-deal investor roadshow	6-Nov	Luxemburg, LUX
Bio-Europe	11-13-Nov	Hamburg, DE
Finance Avenue 2019	17-Nov	Brussels, BE
Jefferies 2019 Healthcare Conference	20-21-Nov	London, UK
World Allergy Congress (WAC)	12-14-Dec	Lyon, FR

\*\*\*

## About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

Further information can be found at [www.asitbiotech.com](http://www.asitbiotech.com).

Follow us on [LinkedIn](#)

## Contacts

### Company

Michel Baijot, CEO  
ASIT biotech  
Tel.: +32 2 264 03 90  
[investors@asitbiotech.com](mailto:investors@asitbiotech.com)



### Investor Relations

LifeSci Advisors LLC  
Hans Herklots  
Tel.: +41 79 598 7149  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

### Media Relations

Sophie Baumont  
Tel.: +33 627 74 74 49  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

## Legal notice

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction. This announcement does not constitute a prospectus. Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be.

## Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.